Bowen Hanes & CO Inc Bristol Myers Squibb CO Transaction History

Bowen Hanes & CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $6 - $3,842	-50 Reduced 0.52%	9,540 $678,000
Q2 2022 Aug 12, 2022	BUY	$72.62 - $79.98 $7,262 - $7,998	100 Added 1.05%	9,590 $738,000
Q4 2020 Feb 08, 2021	SELL	$57.74 - $65.43 $2,713 - $3,075	-47 Reduced 0.49%	9,490 $589,000
Q3 2020 Nov 02, 2020	BUY	$57.43 - $63.64 $2,699 - $2,991	47 Added 0.5%	9,537 $575,000
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $53,462 - $63,387	-1,250 Reduced 11.64%	9,490 $481,000
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $89,240 - $98,680	-2,000 Reduced 15.7%	10,740 $487,000
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $518,879 - $618,700	-11,500 Reduced 47.44%	12,740 $608,000
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $658,260 - $853,605	13,500 Added 125.7%	24,240 $1.26 Million
Q3 2018 Nov 08, 2018	SELL	$55.19 - $62.25 $3,587 - $4,046	-65 Reduced 0.6%	10,740 $667,000
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $596,760 - $688,710	10,805	10,805 $689,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Bowen Hanes & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Bowen Hanes & CO Inc with notifications on news.